Peptides for Gut Health — Evidence Review
Gut-related claims dominate peptide marketing. The actual evidence — narrowed to specific gastrointestinal mechanisms and animal-model or early-human data — is more focused than the marketing implies.
Gut-related claims dominate peptide marketing. The actual evidence — narrowed to specific gastrointestinal mechanisms and animal-model or early-human data — is more focused than the marketing implies.
This guide covers the peptides with documented gut-specific mechanisms, the conditions where evidence is strongest, and what's still speculative.
Peptides with the strongest evidence
BPC-157
Body Protection Compound was originally isolated from gastric juice, and the gut-specific evidence is the largest in the peptide literature. Animal studies report:
- Healing of cysteamine-induced and NSAID-induced gastric ulcers
- Attenuation of NSAID-enteropathy in small intestine
- Improved outcomes in colitis and IBD models
- Restored tight-junction integrity in barrier-dysfunction models
The gut animal-model case is probably the strongest single use case for BPC-157. Human trials remain absent. Oral BPC-157 is more pharmacokinetically plausible for gut-specific effects than injectable (gastric stability is preserved due to proline content), though most published animal work used injectable.
KPV
α-MSH fragment with anti-inflammatory action via melanocortin receptor signaling. Multiple preclinical studies in colitis and IBD models report reduced disease severity, improved histologic scores, and lower pro-inflammatory cytokine production. Phase 1/2 human trials in IBD are emerging.
KPV is one of the more mechanistically targeted gut-inflammation peptides. The case is preclinical but consistent.
Larazotide
Zonulin antagonist that targets intestinal tight-junction regulation. Has been studied in celiac disease (Phase 3 CeDLara trial completed but did not meet primary endpoint, raising questions). Studied in non-celiac gluten sensitivity and IBS contexts. Mechanism is well-defined; clinical efficacy is less consistent than mechanism-based hopes predicted.
Supporting cast
LL-37
Antimicrobial peptide with roles in gut immune defense and barrier function. Therapeutic applications in gut disease are still being characterized. Context-dependent (anti-inflammatory or pro-inflammatory depending on dose and disease state).
What the evidence does not support
- Claims that BPC-157 "heals leaky gut" in humans (no controlled human data exists for this specific outcome)
- Use as a substitute for evaluation of gut symptoms — IBD, celiac disease, microbial overgrowth, malabsorption all have specific diagnostic and treatment pathways
- "Gut healing protocols" combining 4–5 peptides without published evidence supporting the combinations
- Use during active GI cancer (pro-angiogenic concern with BPC-157)
Where to source
For peptides with the largest gut-specific case:
- BPC-157 vendor rankings — 12 ranked vendors
KPV and larazotide vendor data is sparser due to lower independent testing volume.
What we don't know
- Clinical efficacy of BPC-157 in any human gut condition
- Whether oral or injectable administration produces better gut-specific outcomes in humans
- Long-term effects on the gut microbiome
- Whether peptide therapy meaningfully alters disease course in IBD versus controls existing inflammation transiently
Methodology
Read the full methodology.
This page is educational. Gut symptoms warrant proper gastroenterology evaluation. Peptide therapy at best is adjunctive to a clear diagnosis and a treating clinician.